Supplement dated and registered 26 February 2024 to the base prospectus approved by the Swedish Financial Supervisory Authority (the "**Swedish FSA**") on 24 May 2023.

NOBA

This supplement (Swedish FSA ref. no. 24-5454) (the "Supplement") is a supplement to, and shall be read together with, NOBA Bank Group AB (publ)'s (the "Company") base prospectus dated 24 May 2023 (Swedish FSA ref. no. 23-13518) and the pertaining supplementary prospectuses dated 26 May 2023 (Swedish FSA ref. no. 23-15830), 13 September 2023 (Swedish FSA ref. no. 23-24230) and 1 December 2023 (Swedish FSA ref. no. 23-32571) (the "Prospectus") and constitutes a supplement pursuant to Article 23 of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). This Supplement was approved and registered by the Swedish FSA on 26 February 2024. Terms defined in the Prospectus shall have the same meaning when used in this Supplement. In case of conflict between this Supplement and the Prospectus or documents incorporated by reference into the Prospectus, this Supplement shall prevail. This supplement was made public on 26 February 2024 and is available on the Company's website, www.noba.bank (other than the documents incorporated by reference, no information on such website is part of this Supplement or the Prospectus).

This Supplement has been prepared due to the publication of the Company's interim report for the fourth quarter of 2023, which was published on the Company's website on 23 February 2024.

At the time of publication of this Supplement, there are no outstanding offers to purchase or subscribe for transferable securities under the Prospectus and thus there is no right of revocation.

Amendments and supplements to the Prospectus

On page 62, in the table titled "Incorporation by reference", a new row shall be added with the following information:

The Issuer's interim report for the fourth quarter of 2023

(https://mb.cision.com/Main/7708/3934251/2623262.pdf)

as regards the consolidated financial information on page 13 for income statement, page 17 for balance sheet, page 18 for cash flow statement, page 20 for changes in equity capital and pages 23-62 for notes.